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Background: A subarachnoid hemorrhage (SAH) due to the rupture of a cerebral aneurysm (CA) is a devastating
event associated with high rates of mortality. Magnetic resonance angiography (MRA), as a noninvasive technique,
is typically used initially. The object of our study is to evaluate the feasibility of 4D time-resolved MRA with keyhole
(4D-TRAK) for the diagnostic accuracy and reliability of the detection and characterization of cerebral aneurysms
(CAs), with a comparison of 3D time-of-flight MRA (3D-TOF-MRA) by using DSA as a reference.
Methods: 3D-TOF-MRA, 4D-TRAK and 3D-DSA were performed sequentially in 52 patients with suspected CAs.
4D-TRAK was acquired using a combination of sensitivity encoding (SENSE) and CE timing robust angiography
(CENTRA) k-space sampling techniques at a contrast dose of 10 ml at 3 T. Accuracy, sensitivity, specificity of
4D-TRAK and 3D-TOF-MRA were calculated and compared for the detection of CAs on patient-based and
aneurysm-based evaluation using 3D-DSA as a reference.
Results: The overall image quality of 4D-TRAK with a contrast dose of 10 ml was in the diagnostic range but still
cannot be compared with that of 3D-TOF-MRA. In 52 patients with suspected CAs, fifty-eight CAs were confirmed
on 3D-DSA finally. Fifty-one (with 2 false-positives and 9 false-negatives) and 58 (with 1 false-positive and
1 false-negative) CAs were visualized on 4D-TRAK and 3D-TOF-MRA, respectively. Accuracy, sensitivity and specificity
on patient-based evaluation of 4D-TRAK and 3D-TOF-MRA were 92.31%, 93.33%, 85.71% and 98.08%, 100%, 85.71%,
respectively, and 74.07%, 75.00%, 66.67% and 96.30%, 95.83%, 100% on aneurysm-based evaluation in patients with
multiple CAs, respectively. Subgroup analysis revealed that for 19 very small CAs (maximal diameter <3 mm,
measured on 3D-DSA), 9 were missed on 4D-TRAK and 1 on 3D-TOF-MRA (P = 0.008). However, for 39 CAs with
maximal diameter≥ 3 mm, the diagnostic accuracy is equally (39 on 4D-TRAK vs. 39 on 3D-TOF-MRA) (P = 1). In four
larger CAs with maximal diameter≥ 10 mm, 4D-TRAK provided a better characterization of morphology than
3D-TOF-MRA.
Conclusion: 4D-TRAK at a lower contrast dose of 10 ml with a combination of SENSE and CENTRA at 3 T could
provide similar diagnostic accuracy rate for CAs with maximal diameter≥ 3 mm, and a better characterization of
morphology for larger CAs with maximal diameter≥ 10 mm compared to 3D-TOF-MRA. However, further study is
still needed to improve the “vascular edge” artifact and the compromise in spatial resolution in depiction of CAs
with maximal diameter<3 mm.
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A subarachnoid hemorrhage (SAH) due to the rupture
of a cerebral aneurysm (CA) is a devastating event asso-
ciated with high rates of mortality. Digital subtraction
angiography (DSA) combined with post-processing tech-
niques remains to be the gold standard for detecting and
evaluating CAs [1,2]. However, risks include vascular in-
jury, contrast nephrotoxicity, exposure to ionizing radi-
ation and an overall 0.2% risk of transient and
permanent neurological complications [3]. Therefore, as
a noninvasive technique, magnetic resonance angiog-
raphy (MRA) is typically used initially. Although numer-
ous studies have proved that 3D time-of-flight MRA
(3D-TOF-MRA) is an effective technique in the detec-
tion and characterization of CAs [4,5], disadvantages in-
cluding long acquisition time, small FOV and flow
related artifact remain the problem. The 4D time-
resolved MRA with keyhole (4D-TRAK) and a combin-
ation of sensitivity encoding (SENSE) and CE timing
robust angiography (CENTRA) k-space sampling has
demonstrated its wide clinical potential in the
characterization of hemodialysis shunts, pulmonary vas-
cular pathologies and cerebral arteriovenous malforma-
tions (AVMs) [6-9]. The clinical potential in CAs of this
combination of such image acceleration methods
includes: 1) better characterization of the morphology of
larger CAs better due to its reduced flow related artifact;
2) preoperative assessment of endovascular therapy of
CAs by mimicking DSA because of its high spatial and
temporal resolution at a larger FOV; 3) fewer motion
artifacts as a consequence of the shortened acquisition
time for patients with acute aneurysmal SAH. The pur-
pose of our study was to evaluate the feasibility of 4D-
TRAK for the diagnostic accuracy and reliability of the
detection and characterization of CAs, with a compari-
son of 3D-TOF-MRA by using DSA as a reference and
to discuss their respective advantages and disadvantages.
Methods
Study subjects
From June 2008 to February 2010, 52 patients with sus-
pected CAs (20 men, 32 women; age range 31–78 years)
were finally enrolled into our study and 6 of them were
with acute SAH detected by CT scan. 3D-TOF-MRA,
4D-TRAK and 3D-DSA were performed sequentially to
detect the CA occurrence. The study was conducted in
accordance with the recommendations of the Declaration
of Helsinki, and was approved by the ethics committees
in the hospitals. All patients gave written informed con-
sent. Exclusion criteria included age below 18 years, con-
traindications to MRA examination (e.g. pacemakers,
metallic implants), known intolerance to gadolinium
contrast agents, with stage 5 CKD (Chronic Kidney Dis-
ease, effective glomerular filtration rate<15 ml/min/1.73 m [2]) or on dialysis, no informed consent from pa-
tient or qualifying family members, poor neurological
condition (GCS < 12), without DSA information acquired




All MRA examinations were performed on a 3.0 T system
(Achieva X-Series, Philips Healthcare, The Netherlands)
with a Sense-Head-8 receiver head coil. 3D-TOF-MRA
was conducted using a 3D-T1-FFE sequence with TR/TE,
35/7; flip angle, 20°; field-of-view (FOV), 250× 190× 108;
four slabs (180 slices); slice thickness, 0.8 mm; matrix,
732× 1024; and acquisition time, 8 min 56 s. We used the
4D-TRAK technique combined with CENTRA k-space
sampling and sensitivity encoding (SENSE) to accelerate
the image acquisition. 4D-TRAK was acquired using the
CENTRA keyhole method with 20% in the sagittal plane.
A central space is randomly filled during the whole pas-
sage of the contrast bolus over time and the periphery of
k-space was collected in the reference dataset at the end
of the acquisition. Sensitivity encoding (SENSE) was used
with an acceleration factor (AF) of 4 in the phase-
encoding direction and an AF of 2 in the slice-encoding
direction yielding a total AF of 8. The acquisition para-
meters of the 4D-TRAK technique were as follows: 3D-
T1-GE sequence with TR/TE, 3.1/1.2; flip angle, 25°; FOV,
230× 190× 108; four slabs (273 slices); slice thickness,
0.8 mm; matrix, 201 × 320; and acquisition time, 40 s
(reference scanning time, 12 s; 2 s per phase for 14 phases
in total). The 4D-TRAK sequence was started immediately
after the start of the injection. A 10-ml bolus of gadopente-
tate dimeglumine (Gd-DTPA, Magnevist, Bayer-Schering,
Germany) was administered at 3 ml/s and followed by a
20 ml saline injection using a dual-barrel power injection
machine at the same rate.
The acquired image data sets were transferred to a
workstation (EWS, Philips Medical), where 3D image re-
construction was performed on a 1024 × 1024 matrix
with volume rendering (VR) and maximum intensity
projection (MIP) using a specialist software package
(Volume Inspection, Philips Medical).
DSA
For patients with acute SAH, an interventional neurora-
diologist performed DSA within 24 hours after MRA
examination, and for those with suspected un-ruptured
CAs, DSA was performed within 2 weeks after MRA
(between 1 h and 14 d post-MRA; median, 10.6 days).
Conventional 2D-DSA was performed on a monoplanar
unit (Axiom Artis VB22N, Siemens Healthcare, Germany)
with a 1024×1024 matrix and 17–20 cm FOV. Contrast
medium was injected for a total of 10 ml for internal
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(VA, 2–3 ml/s) respectively. Rotational angiography was
performed with an 8-s, 200° rotational run, acquiring 200
images and with the injection of 3–4 ml contrast material
per second (total 16–20 ml/artery). 3D images were recon-
structed by VR on a workstation with a 128 [3] × 512 [3]
matrix (SyngoXWP VA70B, Siemens).
All patients with possible CAs underwent 2D-DSA (in-
cluding posterior-anterior, lateral and working positions)
and 3D-DSA of the affected arteries. 2D-DSA (including
posterior-anterior and lateral positions) was performed
for the rest of the arteries, and further 3D-DSA would
be performed with any positive findings on 2D-DSA.
Two experienced observers, who were unaware of all
clinical information, identified and evaluated the CAs
together.Image review
We considered a CA to be a saccular protrusion
from the side wall or bifurcation of the cerebral ar-
teries without artery emerging at its top. An infun-
dibulum of maximum diameter > 3 mm would be
considered as a remaining CA and concluded into the
statistical analysis in our study. We defined a negative
case as a patient with no CA regardless of other cere-
brovascular diseases. We ensured that all observers
understood these definitions, to achieve consistency of
interpretation.
Two experienced observers with no knowledge of the
clinical history and DSA results interpreted the rota-
tional 4D-TRAK and 3D-TOF-MRA datasets randomly
and independently on an offline workstation, using VR
with the single artery highlighting approach from mul-
tiple viewing angles. MIPs and source images were pre-
sented to the observers with appropriate adjustable
thresholds of window width and level. When the two
observers could not agree on the presence of a CA, a
third observer blind to clinical history and DSA results
would be invited and the final decision was reached by a
majority.
Image quality of 4D-TRAK and 3D-TOF-MRA was
assessed on a four-point scale: 1’, inacceptable; 2’, accept-
able; 3’, good; and 4’, excellent. The following factors were
taken into consideration: background suppression; dis-
play of parent artery; display of small terminal branches;
venous contamination; and artifacts. Images with a score
of 2–4 were considered interpretable. Diagnostic confi-
dence in the presence of a CA on 4D-TRAK and
3D-TOF-MRA was assessed using a previously reported
five-point scale: 5, aneurysm definitely absent; 4, aneurysm
probably absent; 3, uncertain; 2, aneurysm probably
present; and 1, aneurysm definitely present. Cases with
one or more aneurysm identified as probably or definitelypresent were considered positive; all others were consid-
ered negative.Statistical analysis
The diagnostic performance of 3D-TOF-MRA and 4D-
TRAK at 3.0 T were compared with that of 3D-DSA. In a
patient-based evaluation, a patient with at least one CA
detected by both MRA and DSA was considered as a
true-positive (TP) case. A patient with no CA detected
by MRA and DSA was considered as a true-negative (TF)
case. A patient with at least one CA detected by MRA
and no CA detected by DSA was considered as a false-
positive (FP) case. A patient with no CA detected by
MRA and at least one CA detected by DSA was consid-
ered as a false-negative (FN) case. Accuracy, sensitivity,
specificity, positive predictive value (PPV) and negative
predictive value (NPV) were compared on patient-by-
patient level. For patients with multiple CAs, an
aneurysm-based evaluation was made as well. Inter-
observer reliability was calculated for paired observers of
3D-TOF-MRA and 4D-TRAK using the kappa (κ) statis-
tic. A κ value of 0.8 or above indicated excellent agree-
ment; 0.6–0.8, good agreement; 0.4–0.6, fair agreement;
and < 0.4, poor agreement. The statistical analyses were
performed using SPSS version 13.0 (SPSS Inc., Chicago,
Illinois).Results
Fifty-eight CAs were finally found in 52 patients by 3D-
DSA, including no CA detected in 7 patients, 1 CA in
each of the 34 patients, 2 CAs in each of the 10 patients,
and 4 CAs in 1 patient. Nineteen (32.8%) of the 58 aneur-
ysms were< 3 mm in maximal diameter, 25 (43.1%)≥3 mm
and<5 mm, 10 (17.2%)≥5 mm and<10 mm, and 4
(6.9%)≥10 mm. Nine (15.5%) aneurysms located at the an-
terior cerebral artery, 6 (10.3%) at the middle cerebral ar-
tery, 35 (60.3%) at the internal carotid artery and 8 (13.8%)
at the vertebrobasilar system.
The diagnostic accuracy, sensitivity, specificity, PPV
and NPV of 4D-TRAK and 3D-TOF-MRA at 3 T for the
detection of CA on a patient-based evaluation is
described in Table 1. An evaluation based on aneurysm-
by-aneurysm level for multiple CAs is described in
Table 2 and 3. Subgroup analysis revealed that for 19
very small CAs (maximal diameter <3 mm, measured on
3D-DSA), 9 was missed on 4D-TRAK and 1 on 3D-
TOF-MRA (P = 0.008). However, for 39 CAs with max-
imal diameter ≥ 3 mm, the diagnostic accuracy is equally
(39 on 4D-TRAK vs. 39 on 3D-TOF-MRA) (P = 1). The
inter-observer reliability of patient-based evaluation,
based on the κ statistic for paired observers, was 0.91
and 0.95 on 4D-TRAK and 3D-TOF-MRA in patient-
based evaluation, respectively; 0.89 and 0.96 on 4D-
Table 1 Diagnostic performance of 4D-TRAK and 3D-TOF-MRA for the detection of CAs identified on 3D-DSA in the
patient-based evaluation
Technique N TP TN FN k Sensitivity Specify% Specify% PPV% NPV% Accuracy%
4D-TRAK 52 42 6 1 3 0.91 93.33 85.71 96.67 66.67 92.31
3D-TOF-MRA 52 45 6 1 0 0.95 100.00 85.71 97.83 100 98.08
Note: N: number; TP: true-positive; TN: true-negative; FP: false-positive; FN: false-negative; κ: kappa statistic; PPV: positive predictive value; NPV: negative predictive
value.
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in patients with multiple CAs, respectively.
Summary of misdiagnosed aneurysms on 3D-TOF-
MRA and 4D-TRAK is detailed in Table 4. In 52
patients, 58 CAs were visualized on 3D-TOF-MRA, 51
on 4D-TRAK (Figure 1). On 3D-TOF-MRA, 1 patient
(Case No.41) without any aneurysm was misdiagnosedTable 2 Diagnostic performance of 4D-TRAK and 3D-TOF-







10/F/65 ≥ 3 L C7 segment TP TP
≥ 3 Top of Basilar artery TP TP
16/F/54 < 3 L C7 segment FN TP
< 3 L C5 segment TP TP
/ R C5 segment TN TN
22/M/64 < 3 L M1 segment FN TP
< 3 L C7 segment TP TP
26/M/34 ≥ 3 L C6 segment TP TP
≥ 3 R C5 segment TP TP
30/M/45 < 3 L P4 segment FN FN
< 3 L P2 segment FN TP
< 3 L P3 segment TP TP
/ R C6 segment TN TN
< 3 R M1 segment FN TP
31/F/59 / L C7 segment FP TN
≥ 3 R M1 segment TP TP
≥ 3 R C7 segment TP TP
34/M/56 ≥ 3 R C4 segment TP TP
≥ 3 L V4 segment TP TP
37/F/45 < 3 L Acom FN TP
≥ 3 R C7 segment TP TP
43/M/40 < 3 L C6 segment TP TP
< 3 R Acom TP TP
45/M/40 ≥ 3 L C6 segment TP TP
≥ 3 R C4 segment TP TP
52/M/46 < 3 L M1 segment TP TP
≥ 3 R Acom TP TP
Note: M: male; F: female; L: left; R: right; Acom: anterior communicating artery;
TP: true-positive; TN: true-negative; FP: false-positive; FN: false-negative.due to an acute turn of the siphon at C4. One aneurysm
in 1 patient located at left P4 segment (Case No.30) was
missed by both the two methods due to its small size
and peripheral location. On 4D-TRAK, 2 patients (Case
No. 31 and 33) were misdiagnosed as having a aneurysm
due to excessively tortuosity at the origin of the poster-
ior communicating artery, and 9 aneurysms were missed
in 7 patients (Case No. 3, 16, 21, 22, 27, 30 and 37) with
maximal diameter < 3 mm (Figure 2). In 4 patients with
a larger aneurysm (≥ 10 mm in diameter), the outline
and size can be better ascertained by 4D-TRAK than by
3D-TOF-MRA (Figure 3).
In a semi-quantitative score of image quality of 3D-
TOF-MRA images, 40 of 52 cases were regarded as ex-
cellent (76.0%), while 10 cases were good (19.2%) and 2
cases were acceptable (3.8%). By contrast, the number of
excellent cases on 4D-TRAK was only 21 of 52 (40.4%),
with 24 good cases (46.2%) and 7 acceptable cases
(13.5%) (P < 0.001). For 6 restless patients with SAH, 4
cases were acceptable, and 2 cases were good on 3D
–TOF-MRA (8 min 56 s). On 4D-TRAK (40 s), 2 cases
were acceptable, and 4 cases were good.
Discussion
Time-resolved MRA (TR-MRA) is an alternative MRA
technique which uses a keyhole imaging approach to
sample the center of k-space more frequently compared
with high-spatial-frequency information peripherally to
obtain MRA images with high temporal resolution, such
as 4D time-resolved MRA with keyhole (4D-TRAK),
time-resolved imaging with stochastic trajectories
(TWIST), time-resolved echo-shared angiography tech-
nique (TREAT), time-resolved imaging of contrast kinet-
ics (TRICKS) [8,10-13]. 4D-TRAK with a combination
of parallel imaging and CENTRA at high field strength
has demonstrated its wide clinical potential in the
characterization of multiple vascular lesions because of
the high temporal and spatial resolution obtained simul-
taneously in previous studies [6-9]. Most ruptured CAs
in clinical are ≥ 3 mm in diameter. In our study, the
diagnostic accuracy of TRAK for these CAs is equal to
that of 3D-TOF-MRA which has been proved to be of
excellent sensitivity, accuracy, and correlation with 3D-
DSA, as it was demonstrated in the previous studies in a
large cohort of patients in our center [14,15]. For unco-
operative patients with acute SAH and renal impairment
Table 3 Diagnostic performance of 4D-TRAK and 3D-TOF-MRA for the detection of CAs identified on 3D-DSA in the
aneurysm-based evaluation in patients with multiple CAs
Technique N TP TN FN k Sensitivity Specify% Specify% PPV% NPV% Accuracy%
4D-TRAK 19 18 2 1 6 0.89 75.00 66.67 94.74 25.00 74.07
3D-TOF-MRA 23 23 3 0 1 0.96 95.83 100.00 100.00 75.00 96.30
Note: N: number; TP: true-positive; TN: true-negative; FP: false-positive; FN: false-negative; κ: kappa statistic; PPV: positive predictive value; NPV: negative predictive
value.
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raphy (CTA) and 3D-TOF-MRA could not be consid-
ered as the first option because of the renal impairment
associated with the iodinated contrast agents and the
possibility of more motion artifacts due to a relatively
longer acquisition time (8 min 56 s in our study), re-
spectively. Considering the increasing current concern
linking high-dose gadolinium (Gd) chelates to NSF in
patients with advanced renal failure [16,17], a MRA
protocol with low-dose contrast medium was desired for
CAs patients with renal impairment. However, the desir-
able dose is frequently too small to perform both a tim-
ing bolus and non time-resolved contrast-enhanced
MRA (CE-MRA). Although it was reported that the low-
dose contrast medium with the associated shorter dur-
ation of bolus may have contributed to a compromise of
signal-to-noise ratio (SNR) and contrast-to-noise ratio
(CNR) and lead to a suboptimal small-vessel conspicuity
[18], benefiting from higher magnetic fields with an
associated gain in SNR as well as effects on T1-
relaxation of contrast [19,20] and subtraction imaging
for background suppression and contrast enhancement
[21], the small dose of contrast agent utilized has proved
to be sufficient to provide dynamic, functional, as well as
morphological information in a wide range of vascular
diseases in TR-MRA [22,23]. In our result, 4D-TRAKTable 4 Summary of false-positive and false-negative aneurys
Case No./Gender/Age 4D-TRAK 3D-TOF-MRA Location
31/F/59 FP TN L C7 segme
33/F/58 FP TN L C7 segme
30/M/40 FN FN L P4 segme
16/F/54 FN TP L C7 segme
37/F/45 FN TP L Acom
22/M/64 FN TP L M1 segm
30/M/45 FN TP L P2 segme
21/M/60 FN TP R C4 segme
3/M/35 FN TP L C5 segme
27/M/45 FN TP R C5 segme
30/M/45 FN TP R M1 segm
41/M/58 TN FP L C4 segme
Note: M: male; F: female; L: left; R: right; Acom: anterior communicating artery; Pcom
positive; FN: false-negative.with a single injection of 10 ml of Gd-DPTA and a rela-
tively shorter acquisition time of 40s was sufficient to
provide a frame rate up to 2 seconds and morphological
information as well and could become a supplementary
method for some uncooperative patients with acute
SAH and with renal inadequacy.
However, for small CAs with maximal diameter
<3 mm, it does not yet have a diagnostic accuracy com-
parable with 3D-TOF-MRA. The “vascular edge” artifact
(blurring or irregular enhancement of vascular edges)
and a compromise of spatial resolution compared with
high resolution imaging such as 3D-TOF-MRA may be a
diagnostic limitation for the overall image quality of 4D-
TRAK and confident evaluation of smaller CAs. The
peripheral parts of k-space, necessary for spatial reso-
lution, are acquired with the keyhole reference scan after
all dynamics in CENTRA keyhole. The sequence that
combined CENTRA keyhole and SENSE in our study
was likely to provide images with an increased back-
ground noise level and reduced vessel delineation due to
absence of gadolinium in wash-out phase compared with
CE-MRA. A CA is defined as a saccular protrusion from
the side wall or bifurcation of the cerebral arteries with-
out artery emerging at its top. Irregular enhancement of
vascular edges would reduce the slope-rates of protru-
sion on vessel edge, as a result of decreasing thems on 4D-TRAK and 3D-TOF-MRA
Size (mm) Causes
nt ≥ 3 Excessively tortuosity at the origin of the Pcom
nt ≥ 3
nt < 3 Distal location and small size
nt < 3 “vascular edge” artifact and spatial resolution








nt ≥ 3 Acute turn of the siphon at C4 segment
: posterior communicating artery; TP: true-positive; TN: true-negative; FP: false-
Figure 1 A 50-year-old female patient: A. VR DSA, B. VR 3D-TOF-MRA, C. MIP 3D-TOF-MRA, D. VR 4D-TRAK and E. MIP 4D-TRAK
showed a CA located at the bifurcation of the left middle cerebral artery.
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unsmooth arterial walls due to atherosclerosis, especially
for CAs with a smaller size.
4D-TRAK could also be potential in depiction the
morphology of larger CAs in patients with renal insuffi-
ciency. Compared with 3D-TOF-MRA, the decreased
sensitivity to saturation and turbulence effect can be the
advantage of 4D-TRAK benefiting from its different im-
aging principle [24,25]. Within larger aneurysms, espe-
cially those with partial thrombosis, complex flow is
usual found [26]. Similar to Jäge’s results [27], we found
4D-TRAK to characterize the morphology of lesions bet-
ter than 3D-TOF-MRA compared to 3D-DSA in four
larger aneurysms (≥ 10 mm). However, the diagnostic
sensitivity of 3D-TOF-MRA was not decreased in these
cases.
After referencing the previous studies [28-31], except
the decreasing risk of NSF for patients with renal failure,
advantages of 4D-TRAK compared with non time-
resolved CE-MRA in the detection of CAs include: 1) no
need for individual assessment of bolus arrival time;
Timing of the Gd bolus relative to acquisition of centralFigure 2 A 45-year-old male patient: A. VR DSA, B. VR 3D-TOF-MRA a
left middle cerebral artery. D. VR 4D-TRAK and E. MIP 4D-TRAK missek-space is critical for CE- MRA for maximum arterial
signal with minimal venous signal [28,29]. It can be per-
formed by a separate timing bolus injection or by bolus-
tracking sequences that allow automatic or manual trig-
gering when contrast material is seen in the vessels to be
imaged. Compared with CE MRA,no additional bolus
timing and time-consuming sequence adjustments are
necessary in time-resolved imaging. One simply injects
the contrast material and performs the scan simultan-
eously, because as a result of the high temporal update
rate (2 s in our study), one of the volumes will coincide
with the arrival of contrast material. For CAs patients
accompany with any of the following: pediatric patients
with fast contrast media passage, patients with impaired
cardiac output, and patients with high dilution volumes,
the facilitated application of contrast media without the
need for an optimal bolus timing may be especially help-
ful [30]. 2) less arterial and venous overlap; Although
CE-MRA has a high spatial resolution for greater ana-
tomical definition of vessels, there is also an increased
chance for arterial and venous overlap, which can limit
the diagnostic accuracy of CAs [31]. 3) to have thend C. MIP 3D-TOF-MRA showed a CA located at the bifurcation of
d the aneurysm.
Figure 3 A 65-year-old female patient: A. VR DSA, D. VR 4D-TRAK and E. MIP 4D-TRAK have better characterization of the CA (11 mm
in maximum diameter) located at the top of the basal artery than B.VR 3D-TOF-MRA and C. MIP 3D-TOF-MRA.
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vascular strategy for CAs because of the ability to follow
the course of blood flow with an angiographic overview
similar to that of DSA. However, further study is still
needed to obtain the higher spatial and temporal reso-
lution for a better mimic of process of angiography.
We acknowledge the following limitations of our
study. 1) Our study didn’t obtain conventional non-time
resolved CE-MRA sequences at the same time, allowing
for avoiding the second contrast injection. 2) Our data
were obtained from a relatively small sample size.
Conclusion
4D-TRAK at a lower contrast dose of 10 ml with a com-
bination of SENSE and CENTRA at 3 T could provide
similar diagnostic accuracy rate for CAs with maximal
diameter ≥ 3 mm, and a better characterization of morph-
ology for larger CAs with maximal diameter ≥ 10 mm
compared to 3D-TOF-MRA. However, further study is
still needed to improve the “vascular edge” artifact and
the compromise in spatial resolution in depiction of CAs
with maximal diameter< 3 mm.
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